세계의 다중암 스크리닝 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 검사 유형별, 기술별, 샘플별, 방법별, 암 유형별, 용도별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)

The Global Multicancer Screening Market was valued at USD 1.41 billion in 2024 and is projected to reach USD 3.29 billion by 2030, registering a CAGR of 15.12% during the forecast period. The market is expanding rapidly, supported by heightened awareness around early cancer detection, growing incidence rates of various cancer types, and technological advancements in genomic analysis. Healthcare systems are increasingly investing in non-invasive early detection methods, including liquid biopsy, next-generation sequencing (NGS), and AI-integrated bioinformatics platforms that facilitate screening for multiple cancers simultaneously.

Government-backed initiatives, such as the Cancer Moonshot program and other international funding projects, are further accelerating research and commercial deployment. Strategic partnerships between diagnostic developers and academic institutions are fostering robust clinical validation and broader adoption. These efforts, combined with the shift toward preventive care and population-level screening strategies, are driving strong momentum for multicancer early detection (MCED) tests in both developed and emerging markets.

Key Market Drivers

Increasing Prevalence of Chronic Diseases

The growing global burden of cancer continues to be a major driver for the multicancer screening market. Rising incidences of cancer types such as breast, lung, colorectal, prostate, and stomach cancer are fueling the demand for comprehensive screening solutions. For example, in 2023 alone, approximately 300,590 new cases of breast cancer were diagnosed in the U.S. According to the World Health Organization, global cancer data from 2020 showed 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, and over 1 million cases each for colon, prostate, skin (non-melanoma), and stomach cancers.

Countries like Denmark, Ireland, and Australia continue to record some of the highest cancer incidence rates globally, indicating a pressing need for early, accurate, and efficient detection methods. Multicancer screening platforms offer the potential to identify a wide array of cancers at earlier stages, improving prognosis and reducing mortality rates. As cancer rates rise, especially in aging and urbanizing populations, the need for reliable MCED solutions will continue to grow, reinforcing market demand.

Key Market Challenges

Lack of Standardization and Clinical Validation

One of the primary challenges faced by the multicancer screening market is the lack of harmonized standards and comprehensive clinical validation for newer screening tests. Despite significant innovation, the absence of universal testing protocols and diagnostic benchmarks across geographies leads to inconsistent results, limiting test reliability. Without standardized procedures, healthcare providers may remain cautious in adopting multicancer screening technologies.

Moreover, many MCED platforms lack validation through large-scale clinical trials, which are essential for establishing clinical efficacy, sensitivity, and specificity. Regulatory agencies demand substantial evidence before approving these tools for widespread use. Without such validation, uncertainty persists regarding the accuracy and practical application of these tests in real-world settings. This slows down market adoption and hinders regulatory acceptance, particularly in diverse population groups with varying risk profiles.

Key Market Trends

Integration of Liquid Biopsy and Genomic Technologies

A prominent trend shaping the multicancer screening landscape is the convergence of liquid biopsy and advanced genomic technologies. Liquid biopsy methods analyze biomarkers such as circulating tumor DNA (ctDNA), RNA, and exosomes from blood or other fluids, offering a minimally invasive approach to early cancer detection. These techniques allow for cancer identification even before symptoms emerge, and they support ongoing disease monitoring and treatment assessment.

When paired with high-throughput genomic tools such as next-generation sequencing (NGS), the accuracy and scope of liquid biopsy expand significantly. NGS enables comprehensive mutation analysis and enhances the detection of multiple cancer types from a single sample. As these technologies become more cost-effective and refined, their adoption is increasing for large-scale, multi-cancer screening. This integration improves test efficiency, reduces patient burden, and supports broader implementation of population-wide cancer detection programs.

Key Market Players

• Agilent Technologies, Inc.
• Atara Biotherapeutics, Inc.
• Burning Rock Biotech Limited
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Fulgent Genetics, Inc.
• Genecast Biotechnology Co., Ltd.
• Guardant Health, Inc.
• Illumina, Inc.
• Konica Minolta, Inc.

Report Scope

In this report, the Global Multicancer Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multicancer Screening Market, By Test Type:

• Laboratory Developed Tests (LDTs)
• In-Vitro Diagnostics (IVDs)

Multicancer Screening Market, By Technology:

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Fluorescence In-Situ Hybridization (FISH)
• Others

Multicancer Screening Market, By Sample:

• Tissue
• Blood
• Saliva and Buccal Swab
• Others

Multicancer Screening Market, By Method:

• DNA
• RNA
• Proteins

Multicancer Screening Market, By Cancer Type:

• Breast and Gynecologic
• Gastrointestinal
• Endocrine
• Genitourinary
• Skin
• Brain/Nervous System
• Sarcoma
• Hematological Malignancies
• Lung
• Head and Neck
• Other Cancer Types

Multicancer Screening Market, By Application:

• Clinical
• Research

Multicancer Screening Market, By End User:

• Hospitals
• Diagnostic and Clinical Laboratories
• Academic Research Institutions
• Others

Multicancer Screening Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multicancer Screening Market.

Available Customizations

Global Multicancer Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Multicancer Screening Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics (IVDs))
  • 5.2.2. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Others)
  • 5.2.3. By Sample (Tissue, Blood, Saliva and Buccal Swab, Others)
  • 5.2.4. By Method (DNA, RNA, Proteins)
  • 5.2.5. By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, Other Cancer Types)
  • 5.2.6. By Application (Clinical, Research)
  • 5.2.7. By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic Research Institutions, Others)
  • 5.2.8. By Company (2024)
  • 5.2.9. By Region
• 5.3. Market Map

6. North America Multicancer Screening Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Technology
  • 6.2.3. By Sample
  • 6.2.4. By Method
  • 6.2.5. By Cancer Type
  • 6.2.6. By Application
  • 6.2.7. By End User
  • 6.2.8. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Multicancer Screening Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Sample
      • 6.3.1.2.4. By Method
      • 6.3.1.2.5. By Cancer Type
      • 6.3.1.2.6. By Application
      • 6.3.1.2.7. By End User
  • 6.3.2. Mexico Multicancer Screening Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Sample
      • 6.3.2.2.4. By Method
      • 6.3.2.2.5. By Cancer Type
      • 6.3.2.2.6. By Application
      • 6.3.2.2.7. By End User
  • 6.3.3. Canada Multicancer Screening Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Sample
      • 6.3.3.2.4. By Method
      • 6.3.3.2.5. By Cancer Type
      • 6.3.3.2.6. By Application
      • 6.3.3.2.7. By End User

7. Europe Multicancer Screening Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Technology
  • 7.2.3. By Sample
  • 7.2.4. By Method
  • 7.2.5. By Cancer Type
  • 7.2.6. By Application
  • 7.2.7. By End User
  • 7.2.8. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Multicancer Screening Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Sample
      • 7.3.1.2.4. By Method
      • 7.3.1.2.5. By Cancer Type
      • 7.3.1.2.6. By Application
      • 7.3.1.2.7. By End User
  • 7.3.2. Germany Multicancer Screening Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Sample
      • 7.3.2.2.4. By Method
      • 7.3.2.2.5. By Cancer Type
      • 7.3.2.2.6. By Application
      • 7.3.2.2.7. By End User
  • 7.3.3. United Kingdom Multicancer Screening Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Sample
      • 7.3.3.2.4. By Method
      • 7.3.3.2.5. By Cancer Type
      • 7.3.3.2.6. By Application
      • 7.3.3.2.7. By End User
  • 7.3.4. Italy Multicancer Screening Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Sample
      • 7.3.4.2.4. By Method
      • 7.3.4.2.5. By Cancer Type
      • 7.3.4.2.6. By Application
      • 7.3.4.2.7. By End User
  • 7.3.5. Spain Multicancer Screening Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Sample
      • 7.3.5.2.4. By Method
      • 7.3.5.2.5. By Cancer Type
      • 7.3.5.2.6. By Application
      • 7.3.5.2.7. By End User

8. Asia-Pacific Multicancer Screening Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Technology
  • 8.2.3. By Sample
  • 8.2.4. By Method
  • 8.2.5. By Cancer Type
  • 8.2.6. By Application
  • 8.2.7. By End User
  • 8.2.8. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Multicancer Screening Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Sample
      • 8.3.1.2.4. By Method
      • 8.3.1.2.5. By Cancer Type
      • 8.3.1.2.6. By Application
      • 8.3.1.2.7. By End User
  • 8.3.2. India Multicancer Screening Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Sample
      • 8.3.2.2.4. By Method
      • 8.3.2.2.5. By Cancer Type
      • 8.3.2.2.6. By Application
      • 8.3.2.2.7. By End User
  • 8.3.3. South Korea Multicancer Screening Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Sample
      • 8.3.3.2.4. By Method
      • 8.3.3.2.5. By Cancer Type
      • 8.3.3.2.6. By Application
      • 8.3.3.2.7. By End User
  • 8.3.4. Japan Multicancer Screening Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Sample
      • 8.3.4.2.4. By Method
      • 8.3.4.2.5. By Cancer Type
      • 8.3.4.2.6. By Application
      • 8.3.4.2.7. By End User
  • 8.3.5. Australia Multicancer Screening Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Sample
      • 8.3.5.2.4. By Method
      • 8.3.5.2.5. By Cancer Type
      • 8.3.5.2.6. By Application
      • 8.3.5.2.7. By End User

9. South America Multicancer Screening Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Technology
  • 9.2.3. By Sample
  • 9.2.4. By Method
  • 9.2.5. By Cancer Type
  • 9.2.6. By Application
  • 9.2.7. By End User
  • 9.2.8. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Multicancer Screening Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Sample
      • 9.3.1.2.4. By Method
      • 9.3.1.2.5. By Cancer Type
      • 9.3.1.2.6. By Application
      • 9.3.1.2.7. By End User
  • 9.3.2. Argentina Multicancer Screening Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Sample
      • 9.3.2.2.4. By Method
      • 9.3.2.2.5. By Cancer Type
      • 9.3.2.2.6. By Application
      • 9.3.2.2.7. By End User
  • 9.3.3. Colombia Multicancer Screening Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Sample
      • 9.3.3.2.4. By Method
      • 9.3.3.2.5. By Cancer Type
      • 9.3.3.2.6. By Application
      • 9.3.3.2.7. By End User

10. Middle East and Africa Multicancer Screening Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Technology
  • 10.2.3. By Sample
  • 10.2.4. By Method
  • 10.2.5. By Cancer Type
  • 10.2.6. By Application
  • 10.2.7. By End User
  • 10.2.8. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Multicancer Screening Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Sample
      • 10.3.1.2.4. By Method
      • 10.3.1.2.5. By Cancer Type
      • 10.3.1.2.6. By Application
      • 10.3.1.2.7. By End User
  • 10.3.2. Saudi Arabia Multicancer Screening Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Sample
      • 10.3.2.2.4. By Method
      • 10.3.2.2.5. By Cancer Type
      • 10.3.2.2.6. By Application
      • 10.3.2.2.7. By End User
  • 10.3.3. UAE Multicancer Screening Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Sample
      • 10.3.3.2.4. By Method
      • 10.3.3.2.5. By Cancer Type
      • 10.3.3.2.6. By Application
      • 10.3.3.2.7. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Agilent Technologies, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Atara Biotherapeutics, Inc.
• 14.3. Burning Rock Biotech Limited
• 14.4. Exact Sciences Corporation
• 14.5. F. Hoffmann-La Roche Ltd.
• 14.6. Fulgent Genetics, Inc.
• 14.7. Genecast Biotechnology Co., Ltd.
• 14.8. Guardant Health, Inc.
• 14.9. Illumina, Inc.
• 14.10. Konica Minolta, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer